STOCK TITAN

Immuron Ltd - IMRN STOCK NEWS

Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.

Immuron Ltd (ASX: IMRN) provides investors and industry stakeholders with timely updates through this centralized news resource. Track the Australian biopharmaceutical innovator's progress in developing oral immunotherapies targeting gastrointestinal and immune-mediated disorders.

Access verified announcements covering clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Immuron's hyperimmune bovine colostrum platform, product pipeline advancements, and financial disclosures - all essential for understanding the company's position in the immunotherapy sector.

Key focus areas include Travelan® commercialization efforts, research into non-alcoholic fatty liver disease treatments, and novel applications of polyclonal antibody technology. Bookmark this page for efficient monitoring of Immuron's progress in addressing unmet needs across gastroenterology and immunology markets.

Rhea-AI Summary

Immuron , an Australian biopharmaceutical company, will be presenting at the Emerging Growth Conference on May 8, 2024. Investors, analysts, and advisors can interact with the CEO, Steven Lydeamore, during the live event. Questions can be submitted in advance or during the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences
-
News
Rhea-AI Summary

Immuron announces the resignation of Non-Executive Director Stephen Anastasiou to focus on other business interests. Stephen has been with the company since 2013, contributing to the launch of Travelan® in the USA and Canadian markets and dual listing on NASDAQ (IMRN). His departure is aimed at restructuring his business commitments to spend more time with family and pursue personal interests. Immuron Chairman expresses gratitude for Stephen's marketing and clinical contributions and wishes him success in future endeavors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
management
-
News
Rhea-AI Summary
Immuron (ASX: IMC; NASDAQ: IMRN) announces a Live Virtual Event featuring positive Phase 2 Travelan results and upcoming Phase 3 clinical trials. The event will showcase the company's success in developing oral immunotherapeutics for gut-mediated diseases, with significant reductions in diarrhea cases and promising revenue projections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
Rhea-AI Summary
Immuron (IMRN) reports significant sales growth for Travelan®, an immune supplement, in Australia and the USA. FYTD Mar 2024 sales reached AUD$3.6 million, up 154% from the prior year, with Australia leading at AUD$2.8 million, up 234%. Sales on Walmart.com have commenced. The company aims to expand brand awareness and distribution in North America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
-
Rhea-AI Summary
Immuron Limited announces positive interim topline results for Travelan® in preventing moderate to severe diarrhea caused by ETEC. The Phase 2 study showed significant protective efficacy with a single daily dose, supported by funding from the U.S. Department of Defense. The study demonstrated a 36.4% protective efficacy against moderate to severe diarrhea and a 66.7% protective efficacy against severe diarrhea compared to the placebo group. Additionally, there was an 83.3% reduction in subjects needing early antibiotic treatment and a 100% reduction in subjects requiring IV fluids post challenge in the Travelan® group. The study also reported a 55.6% reduction in adverse events associated with the ETEC challenge in the Travelan® group. The Phase 2 study data supported the excellent safety and tolerability profile of Travelan®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
175.76%
Tags
-
Rhea-AI Summary
Immuron Limited announces the participation of their Research & Development Manager at the Australian Biologics Festival 2024, showcasing their innovative work in biopharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
News
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announces record Travelan® sales in YTD Jan 2024, exceeding FY20 sales. Australian sales reached $2.1 million, USA sales at $0.6 million, and Canadian sales recommenced through McKesson.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
none
-
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that their CEO, Steven Lydeamore, will be presenting at the Monsoon Communications Investor function in Sydney, Australia. The presentation slide deck is available on the company's website for public access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
-
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has reported record half yearly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®, with total sales reaching A$2,355,580 in H1, FY24. This marks a significant increase of $1,771,932 compared to H1, FY23 sales and a 51% increase over pre-pandemic period H1, FY20 sales. Australian sales of Travelan® increased by 132% compared to H1, FY23, while USA sales saw a slight decrease of 6% compared to the pre-pandemic peak period H1, FY20. Despite this, the Amazon launch in the USA is progressing well, with sales already ahead of budget. The company anticipates strong sales growth closer to the peak spring/summer travel period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
News
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) completes in-patient phase of US Naval Medical Research Command campylobacter clinical program, prepares for Pre-IND submission to the FDA, and progresses Travelan clinical study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Immuron Ltd

Nasdaq:IMRN

IMRN Rankings

IMRN Stock Data

10.84M
5.84M
0.1%
0.31%
Biotechnology
Healthcare
Link
Australia
Carlton